Cat. No. 3537
Biological ActivityPotent and selective human formyl peptide receptor FPR2 agonist (EC50 values are 1, 2 and > 10 000 nM at mFRP2, hFPR2 and hFPR1 respectively). Induces migration of human monocytes and neutrophils via a chemotactic mechanism and enhances production of proinflammatory cytokines IL-1β and IL-6. Also activates the neutrophil superoxide-generating NADPH-oxidase.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Karlsson et al (2009) The FPR2-specific ligand MMK-1 activates the neutrophil NADPH-oxidase, but triggers no unique pathway for opening of plasma membrane calcium channels. Cell Calcium 45 431. PMID: 19282028.
Hu et al (2001) Synthetic peptide MMK-1 is a highly specific chemotactic agonist for leukocyte FPRL1. J.Leukoc.Biol. 70 155. PMID: 11435499.
Klein et al (1998) Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast. Nature Biotech. 16 1334.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for MMK 1 include:
Leoni et al (2013) Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. J Clin Invest 123 443. PMID: 23241962.
Do you know of a great paper that uses MMK 1 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: MMK 1, supplier, Potent, selective, FPR2, agonists, FPRL, Formyl, Peptide, Receptors, MMK1, Tocris Bioscience, Formyl Peptide Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonistMSG 606
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist
One Day Symposium
March 1, 2017
Amsterdam, The Netherlands